OncoCyte Corporation (OCX): Utang-utang marang kapitalisasi buku

OncoCyte Corporation is developing GraftAssure for non-invasive graft monitoring, offering precise oncodiagnostics for therapy selection. The business is currently scaling molecular tests to reach break-even. The company's debt-to-book capitalization ratio reflects the dynamics of its debt load, while the 0.35 indicator determines the metric's magnitude, helping to assess the issuer's financial stability during periods of volatility.

OncoCyte Corporation focuses on the commercialization of specialized diagnostic tests for transplantology. This ratio measures the share of debt capital within the equity structure, determining the business's degree of financial leverage. It is critical for investors to monitor this balance to assess risks associated with rising marketing expenses. GURU.Markets tools allow users to identify the company's margin of safety through the ratio of borrowed funds to balance sheet capital. The stability of this metric confirms the adequacy of existing reserves.